Instil Bio, Inc. (TIL)

Instil Bio, Inc. (TIL) Healthcare & Pipeline Overview

Instil Bio, Inc. is a clinical-stage biopharmaceutical company specializing in autologous tumor-infiltrating lymphocyte (TIL) therapies for cancer. Their pipeline features ITIL-168 and ITIL-306, targeting solid tumors. Based in Dallas, Texas, Instil Bio aims to revolutionize cancer treatment through personalized cell therapies.

What Is the Investment Thesis for TIL?

Instil Bio presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on autologous TIL therapies offers a novel approach to cancer treatment, potentially addressing the limitations of existing therapies. The clinical development of ITIL-168 and ITIL-306 represents significant value drivers, with potential for breakthrough therapies in melanoma, lung cancer, and gynecological cancers. However, the company's success hinges on positive clinical trial outcomes and regulatory approvals. With a market cap of $53.04M and a beta of 2.03, Instil Bio exhibits substantial volatility, reflecting the inherent risks associated with clinical-stage biopharmaceutical companies. The absence of a dividend further emphasizes the company's focus on reinvesting capital into research and development. Investors should carefully weigh the potential benefits against the risks before considering an investment in Instil Bio.

Based on FMP financials and quantitative analysis

TIL Key Highlights

• Instil Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer.
• The company's lead product candidate, ITIL-168, targets various solid tumor indications, including melanoma and lung cancer.
• ITIL-306 is designed to recognize folate receptor alpha (FOLR1), a protein commonly found on the surface of cancer cells.
• Instil Bio's approach involves isolating, expanding, and infusing TILs back into the patient to target and destroy cancer cells.
• The company is headquartered in Dallas, Texas, and was incorporated in 2018.

Who Are TIL's Competitors?

TIL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TIL's Key Strengths?

• Novel TIL therapy platform with the potential to address unmet needs in cancer treatment.
• Promising clinical data for ITIL-168 and ITIL-306 in solid tumor indications.
• Experienced management team with expertise in cell therapy development.
• Strong intellectual property portfolio protecting its TIL therapies.

What Are TIL's Weaknesses?

• Clinical-stage company with no currently approved products and no revenue.
• High cash burn rate due to ongoing clinical trials and research and development expenses.
• Dependence on successful clinical trial outcomes and regulatory approvals.
• Limited manufacturing capacity for TIL therapies.

What Could Drive TIL Stock Higher?

• Interim data readout from the ITIL-168 Phase 2 clinical trial in melanoma patients.
• Initiation of Phase 1 clinical trial for ITIL-306 in FOLR1-positive gynecological cancers.
• Enrollment of patients in ongoing clinical trials for ITIL-168 and ITIL-306.
• Potential for strategic partnerships and collaborations with other biotechnology and pharmaceutical companies.

What Are the Key Risks for TIL?

• Financial-distress signal — its Altman Z-Score of -4.34 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-39.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive clinical trial results for ITIL-168 and ITIL-306.
• Regulatory delays or rejection of marketing applications for TIL therapies.
• Competition from other biotechnology and pharmaceutical companies developing cancer therapies.
• High cash burn rate and dependence on future financing to fund clinical trials and research and development.

What Are the Growth Opportunities for TIL?

• Expansion of ITIL-168 into New Indications: Instil Bio has the opportunity to expand the clinical development of ITIL-168 into additional solid tumor indications beyond its current targets, such as melanoma and lung cancer. This could significantly increase the potential market size for ITIL-168 and drive revenue growth. The timeline for this expansion depends on the results of ongoing clinical trials and regulatory approvals, but it represents a key growth driver for the company.
• Advancement of ITIL-306 in FOLR1-Positive Cancers: ITIL-306, which targets folate receptor alpha (FOLR1), has the potential to address a significant unmet need in gynecological cancers, non-small cell lung cancer, and renal cancer. Positive clinical trial results and regulatory approvals for ITIL-306 could drive substantial growth for Instil Bio. The company's ability to demonstrate the efficacy and safety of ITIL-306 will be crucial for its success in this market.
• Strategic Partnerships and Collaborations: Instil Bio can pursue strategic partnerships and collaborations with other biotechnology and pharmaceutical companies to accelerate the development and commercialization of its TIL therapies. These partnerships could provide access to additional resources, expertise, and funding, which would enhance the company's growth prospects. The timeline for securing these partnerships is uncertain, but they represent a valuable growth opportunity for Instil Bio.
• Development of Next-Generation TIL Therapies: Instil Bio can invest in the development of next-generation TIL therapies with enhanced efficacy and safety profiles. This could involve incorporating new technologies, such as gene editing or combination therapies, to improve the performance of TILs. The development of these next-generation therapies would position Instil Bio as a leader in the field of cell therapy and drive long-term growth.
• Geographic Expansion into New Markets: Instil Bio has the opportunity to expand its operations into new geographic markets, such as Europe and Asia, to reach a broader patient population. This would require establishing clinical trial sites, regulatory approvals, and commercial infrastructure in these regions. The timeline for geographic expansion depends on the company's financial resources and strategic priorities, but it represents a significant growth opportunity for Instil Bio.

What Opportunities Does TIL Have?

• Expansion of TIL therapies into new solid tumor indications.
• Strategic partnerships and collaborations with other biotechnology and pharmaceutical companies.
• Development of next-generation TIL therapies with enhanced efficacy and safety profiles.
• Geographic expansion into new markets, such as Europe and Asia.

What Threats Does TIL Face?

• Competition from other biotechnology and pharmaceutical companies developing cancer therapies.
• Regulatory hurdles and delays in clinical trials and approvals.
• Adverse events or safety concerns in clinical trials.
• Changes in the regulatory landscape for cell therapies.

What Are TIL's Competitive Advantages?

• Proprietary TIL technology platform that enhances and expands TILs to create potent, personalized cancer treatments.
• Strong intellectual property portfolio protecting its TIL therapies and manufacturing processes.
• Clinical data demonstrating the efficacy and safety of its TIL therapies.
• Experienced management team with a proven track record in cell therapy development.

What Does TIL Do?

Instil Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for cancer patients. Founded in 2018 and headquartered in Dallas, Texas, Instil Bio focuses on harnessing the power of autologous tumor-infiltrating lymphocytes (TILs) to combat solid tumors. TILs are immune cells that naturally infiltrate tumors, and Instil Bio's technology aims to enhance and expand these cells to create potent, personalized cancer treatments. The company's lead product candidate, ITIL-168, is being developed for various solid tumor indications, including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. ITIL-168 leverages the patient's own immune cells to target and destroy cancer cells. Another key asset in Instil Bio's pipeline is ITIL-306, which is designed to recognize folate receptor alpha (FOLR1), a protein commonly found on the surface of cancer cells in gynecological cancers, non-small cell lung cancer, and renal cancer. By targeting FOLR1, ITIL-306 aims to provide a more precise and effective treatment option for these cancers. Instil Bio's approach involves isolating TILs from a patient's tumor, expanding them in the laboratory, and then infusing them back into the patient. This process aims to overcome the limitations of traditional cancer therapies by providing a personalized treatment that specifically targets the patient's tumor. The company is committed to advancing its TIL platform and developing new therapies that can improve outcomes for cancer patients.

What Products and Services Does TIL Offer?

• Develops autologous tumor infiltrating lymphocyte (TIL) therapies for cancer treatment.
• Focuses on harnessing the power of the patient's own immune cells to fight cancer.
• Isolates TILs from a patient's tumor, expands them in the laboratory, and infuses them back into the patient.
• Develops ITIL-168 for solid tumor indications, including melanoma and lung cancer.
• Develops ITIL-306 to recognize folate receptor alpha (FOLR1) in gynecological cancers, lung cancer, and renal cancer.
• Conducts clinical trials to evaluate the safety and efficacy of its TIL therapies.

How Does TIL Make Money?

• Develops and commercializes autologous TIL therapies for cancer treatment.
• Generates revenue through the sale of its TIL therapies to hospitals and cancer centers.
• May enter into strategic partnerships and collaborations with other biotechnology and pharmaceutical companies to accelerate the development and commercialization of its products.
• Secures funding through venture capital, public offerings, and government grants.

What Industry Does TIL Operate In?

Instil Bio operates within the rapidly evolving biotechnology industry, specifically in the field of cell and gene therapy. The market for cell therapies is projected to experience substantial growth, driven by advancements in immunotherapy and personalized medicine. The competitive landscape includes companies developing CAR-T cell therapies, oncolytic viruses, and other innovative approaches to cancer treatment. Instil Bio's focus on TIL therapies differentiates it from companies primarily focused on CAR-T therapies. The company's success depends on its ability to demonstrate the efficacy and safety of its TIL product candidates in clinical trials and secure regulatory approvals.

Who Are TIL's Key Customers?

• Hospitals and cancer centers that treat patients with solid tumors.
• Oncologists who prescribe TIL therapies to their patients.
• Patients with melanoma, lung cancer, gynecological cancers, and other solid tumors.
• Healthcare providers who administer TIL therapies.

FY2026 estForward Outlook

Wall Street analysts project Instil Bio, Inc. revenue of about $4.0M for fiscal 2026, with EPS near $-1.17.

ROE -40%Key Financial Metrics

Return on equity for Instil Bio, Inc. stands at -39.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -64.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 39.87 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -90.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Instil Bio, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.34 places it in the distress zone, a signal of elevated financial risk.

TIL Valuation & Market Position

With a $53.04M market cap, Instil Bio, Inc. sits in the micro-cap segment of the market. Relative to its peer group, TIL's quantitative score of 29/100 is below the peer average of 67/100.

TIL Financials

TIL Latest News

TIL Analyst Consensus

TIL MoonshotScore

Instil Bio, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources